Ruxolitinib cream + Vehicle cream
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Vitiligo
Conditions
Vitiligo
Trial Timeline
Jun 7, 2017 → Sep 8, 2021
NCT ID
NCT03099304About Ruxolitinib cream + Vehicle cream
Ruxolitinib cream + Vehicle cream is a phase 2 stage product being developed by Incyte for Vitiligo. The current trial status is completed. This product is registered under clinical trial identifier NCT03099304. Target conditions include Vitiligo.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06804811 | Phase 3 | Recruiting |
| NCT06959225 | Phase 3 | Recruiting |
| NCT06958211 | Phase 3 | Recruiting |
| NCT06548360 | Phase 3 | Recruiting |
| NCT06238817 | Phase 3 | Completed |
| NCT05764161 | Phase 3 | Completed |
| NCT05755438 | Phase 3 | Completed |
| NCT05635838 | Phase 2 | Completed |
| NCT05593432 | Phase 2 | Completed |
| NCT05593445 | Phase 2 | Completed |
| NCT04896385 | Phase 2 | Completed |
| NCT03745638 | Phase 3 | Completed |
| NCT03745651 | Phase 3 | Completed |
| NCT03099304 | Phase 2 | Completed |
Competing Products
20 competing products in Vitiligo